GL0034 (Utreglutide), a long acting, glucagon-like peptide-1 receptor agonist, improves body weight loss, lipid and liver injury markers in individuals with obesity: A phase 1 multiple ascending dose study

被引：0
|
作者：
Thennati, Rajamannar [1 ]
Burade, Vinod [1 ]
Natarajan, Muthukumaran [1 ]
Shahi, Pradeep [1 ]
Nagaraja, Ravishankara [1 ]
Agrawal, Sudeep [1 ]
Jandrain, Bernard [2 ,3 ]
Duvauchelle, Thierry [4 ]
Pratley, Richard E. [5 ]
Thorens, Bernard [6 ]
Vilsboll, Tina [7 ]
Loomba, Rohit [8 ]
机构：
[1] Sun Pharmaceut Ind Ltd, High Impact Innovat Sustainable Hlth Solut HISH, Vadodara, India
[2] Acad Hosp Liege, Clin Pharmacol Unit, ATC Co, Liege, Belgium
[3] Acad Hosp Liege, Div Diabet Nutr & Metab Disorders, Liege, Belgium
[4] Phaster1, Paris, France
[5] AdventHealth Translat Res Inst, Orlando, FL USA
[6] Univ Lausanne, Ctr Integrat Genom, Lausanne, Switzerland
[7] Univ Copenhagen, Steno Diabet Ctr Copenhagen, Clin Res, Copenhagen, Denmark
[8] Univ Calif San Diego, Sch Med, La Jolla, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-231
引用
收藏
页码：S615 / S616
页数：2
相关论文
共 49 条
  • [1] GL0034 (Utreglutide), a novel, long acting, glucagon-like peptide 1 receptor agonist (GLP-1 RA), results of a phase 1 study in healthy individuals
    Thennati, Rajamannar
    Burade, Vinod
    Natarajan, Muthukumaran
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Panchal, Satish
    Agrawal, Sudeep
    Jandrain, Bernard
    Duvauchelle, Thierry
    Pratley, Richard E.
    Thorens, Bernard
    Vilsboll, Tina
    JOURNAL OF HEPATOLOGY, 2023, 78 : S607 - S608
  • [2] In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist
    Jones, Ben
    Burade, Vinod
    Akalestou, Elina
    Manchanda, Yusman
    Ramchunder, Zenouska
    Carrat, Gaelle
    Nguyen-Tu, Marie-Sophie
    Marchetti, Piero
    Piemonti, Lorenzo
    Leclerc, Isabelle
    Thennati, Rajamannar
    Vilsboll, Tina
    Thorens, Bernard
    Tomas, Alejandra
    Rutter, Guy A.
    DIABETES OBESITY & METABOLISM, 2022, 24 (11): : 2090 - 2101
  • [3] A single ascending dose study of the novel GLP-1 receptor agonist GL0034 (utreglutide) in individuals with obesity without diabetes
    Thennati, R.
    Burade, V.
    Natarajan, M.
    Shahi, P.
    Nagaraja, R.
    Panchal, S.
    Agrawal, S.
    Jandrain, B.
    Duvauchelle, T.
    Garcia-Ocana, A.
    Rutter, G. A.
    Pratley, R. E.
    Thorens, B.
    Vilsboll, T.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S320 - S321
  • [4] A Single Ascending Dose Study of the Novel GLP-1 Receptor Agonist GL0034 (Utreglutide) in Obese Individuals without Diabetes
    Thennati, Rajamannar
    Burade, Vinod S.
    Natarajan, Muthukumaran
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Panchal, Satish T.
    Agrawal, Sudeep K.
    Jandrain, Bernard
    Duvauchelle, Thierry
    Garcia-Ocana, Adolfo
    Rutter, Guy A.
    Pratley, Richard E.
    Thorens, Bernard
    Vilsboll, Tina
    DIABETES, 2023, 72
  • [5] Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist, at 4 x 450 μg Doses Reduces Blood Pressure, Lipids, and Body Weight in Post-menopausal Females: A Phase I Study
    Thennati, Rajamannar
    Burade, Vinod
    Natarajan, Muthukumaran
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Agrawal, Sudeep
    Duvauchelle, Thierry
    Pratley, Richard
    Thorens, Bernard
    Vilsboll, Tina
    CIRCULATION, 2024, 150
  • [6] Phase I Study of Glucagon-like Peptide-1/Glucagon Receptor Dual Agonist BI 456906 in Obesity
    Arrubla, Jorge
    Schoelch, Corinna
    Plum-Moerschel, Leona
    Kapitza, Christoph
    Lamers, Daniela
    Thamer, Claus
    Hennige, Anita M.
    OBESITY, 2021, 29 : 139 - 140
  • [7] GL0034, A novel long-acting glucagon-like peptide 1 receptor agonist exhibits significant efficacy in aged db/db mouse model of non-alcoholic fatty liver disease (NAFLD)
    Thennati, Rajamannar
    Burade, Vinod
    Garcia-Ocana, Adolfo
    Pratley, Richard E.
    Rutter, Guy
    Vilsboll, Tina
    Thorens, Bernard
    JOURNAL OF HEPATOLOGY, 2022, 77 : S710 - S710
  • [8] Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
    Zaffina, Isabella
    Pelle, Maria Chiara
    Armentaro, Giuseppe
    Giofre, Federica
    Cassano, Velia
    Sciacqua, Angela
    Arturi, Franco
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [9] Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity
    Nathan, B. M.
    Rudser, K. D.
    Abuzzahab, M. J.
    Fox, C. K.
    Coombes, B. J.
    Bomberg, E. M.
    Kelly, A. S.
    CLINICAL OBESITY, 2016, 6 (01) : 73 - 78
  • [10] A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy
    Knop, Filip K.
    Urva, Shweta
    Rettiganti, Mallikarjuna
    Benson, Charles T.
    Roell, William C.
    Mather, Kieren J.
    Haupt, Axel
    Pratt, Edward John
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5474 - 5478
12345